SEOM Clinical Guideline of fertility preservation and reproduction in cancer patients (2016)

Clinical and Translational Oncology

Volumn 18, Issue 12, 2016, Pages 1229-1236

  Munoz M ^a   Santaballa, A ^b   Segui M A ^c   Beato, C ^d   de la Cruz, S ^e   Espinosa, J ^f   Fonseca, P J ^g   Perez, J ^h   Quintanar, T ^h   Blasco, A ⁱ  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c Servicio de Oncología Médica   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^e Instituto de Investigación Sanitaria de Navarra   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO DE CIUDAD REAL   (Spain)

^g HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

ⁱ HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

Adolescent child cancer; Cancer patients; Cryopreservation; Fertility preservation; Infertility

Indexed keywords

BEVACIZUMAB; BUSULFAN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GONADORELIN AGONIST; METHOTREXATE; PROCARBAZINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

AMENORRHEA; ARTICLE; AZOOSPERMIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CRYOPRESERVATION; FERTILITY PRESERVATION; FOLLOW UP; HORMONE RELEASE; HUMAN; MENTAL HEALTH; OOCYTE; OVARIECTOMY; OVARY CANCER; OVARY CARCINOMA; PREGNANCY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCTION; SKULL IRRADIATION; SURVIVAL RATE; UTERINE CERVIX CANCER; WHOLE BODY RADIATION; ADVERSE EFFECTS; FEMALE; MALE; NEOPLASMS; PRACTICE GUIDELINE; PROCEDURES; RADIOTHERAPY; SPAIN; SURVIVOR; TRENDS;

ANTINEOPLASTIC AGENTS; FEMALE; FERTILITY PRESERVATION; HUMANS; MALE; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RADIOTHERAPY; SPAIN; SURVIVORS;

EID: 84997830645     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-016-1587-9     Document Type: Article

References (37)

1. Bleyer A, Viny A, Barr R. Introduction. In: Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975–2000. National Cancer Institute, NIH Pub. No. 06-5767, National Institutes of Health, Bethesda; 2006. p. 1.
2. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10. International Agency for Research on Cancer, Lyon, France; 2012.
3. Kenney LB, Cohen L, Shnorhavoriab M, Metzger M, Lockart B, Hijiya N, et al. Male reproductive health after childhood, adolescent, and young adult cancers: a report from the Children’s Oncology Group. J Clin Oncol. 2012;30:3408–16.
4. Metzger ML, Meacham L, Patterson B, Casillas J, Constine L, Hijiya N, et al. Female reproductive health after childhood, adolescent, and young adult cancers: guidelines for the assessment and management of female reproductive complications. J Clin Oncol. 2013;31:1239–47.
5. Goossens J, Delbaere I, Van Lancker A, Beeckman D, Verhaeghe S, Van Hecke A. Cancer patients’ and professional caregivers’ needs, preferences and factors associated with receiving and providing fertility-related information: a mixed methods systematic review. Int J Nurs Stud. 2014;51:300–19.
6. Font-Gonzalez A, Mulder RL, Loeffen EA, Byrne J, van Dulmen-den Broeder E, van den Heuvel-Eibrink MM, et al. Fertility preservation in children, adolescents, and young adults with cancer: quality of clinical practice guidelines and variations in recommendations. Cancer. 2016;122(14):2216–23.
7. Rodriguez-Wallberg KA, Oktay K. Fertility preservation medicine: options for young adults and children with cancer. J Pediatr Hematol Oncol. 2010;32(5):390–6.
8. Kesic V, Rodolakis A, Denschlag D, Schneider A, Morice P, Amant F, et al. Fertility preserving management in gynecologic cancer patients: the need for centralization. Int J Gynecol Cancer. 2010;20(9):1613–9.
9. Schover LR, van der Kaaij M, van Dorst E, Creutzberg C, Huyghe E, Kiserud CE. Sexual dysfunction and infertility as late effects of cancer treatment. Eur J Cancer. 2014;12(Suppl):41–53.
10. Chow EJ, Stratton KL, Leisenring WM, Oeffinger KC, Sklar CA, Donaldson SS, et al. Pregnancy after chemotherapy in male and female survivors of childhood cancer treated between 1970 and 1999: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol. 2016;17(5):567–76.
11. Hulvat MC, Jeruss JS. Maintaining fertility in young women with breast cancer. Curr Treat Options Oncol. 2009;10:308–17.
12. Llarena NC, Estevez SL, Tucker SL, Jeruss JS. Impact of fertility concerns on tamoxifen initiation and persistence. J Natl Cancer Inst. 2015;107:djv202.
13. Thomas-Teinturies C, Setcheou-Allodji R, Svetlova E, Frey MA, Oberlin O, Millischer AE, et al. Ovarian reserve after treatment with alkylating agents during childhood. Hum Reprod. 2015;30:1437–46.
14. Picton HM, Wyns C, Anderson RA, Goossens E, Jahnukainen K, Kliesch S, et al. An European perspective on testicular tissue cryopreservation for fertility preservation in prepubertal and adolescent boys. Hum Reprod. 2015;30:2463–76.
15. Meistrich ML. Male gonadal toxicity. Pediatr Blood Cancer. 2009;53:261–6.
16. Peccatori F, Azim HA Jr, Orecchia R, Hoekstra HJ, Pavlidis N, Kesic V, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up. Ann Oncol. 2013;24:160–70.
17. Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2013;19:2500–10.
18. Tournaye H, Dohle GR, Barratt C. Fertility preservation options for men and women with cancer. Lancet. 2014;384:1295–301.
19. Hourvitz A, Goldschlag DE, Davis OK, Gosden LV, Palermo GD, Rosenwaks Z. Intracytoplasmic sperm injection (ICSI) using cryopreserved sperm from men with malignant neoplasm yields high pregnancy rates. Fertil Steril. 2008;90:557–63.
20. Salama M, Winkler K, Murach KF, Seeber B, Ziehr SC, Wildt L. Female fertility loss and preservation: threats and opportunities. Ann Oncol. 2013;24(3):598–608.
21. Angarita AM, Johnson CA, Fader AN, Christianson MS. Fertility preservation: a key survivorship issue for young women with cancer. Front Oncol. 2016;6:1–10.
22. Dolmans MM, Hollanders de Ouderaen S, Demylle D, Pirard C. Utilization rates and results of long-term embryo cryopreservation before gonadotoxic treatment. J Assist Reprod Genet. 2015;32(8):1233–7.
23. Cobo A, Diaz C. Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials. Fertil Steril. 2011;96:277–85.
24. Cobo A, Meseguer M, Remohi J, Pellicer A. Use of cryo-banked oocytes in an ovum donation programme: a prospective, randomized, controlled, clinical trial. Hum Reprod. 2010;25(9):2239–46.
25. Donnez J, Dolmans MM. Ovarian cortex transplantation: 60 reported live births brings the success and worldwide expansion of the technique towards routine clinical practice. J Assist Reprod Genet. 2015;32(8):1167–70.
26. Hickman LC, Valentine LN, Falcone T. Preservation of gonadal function in women undergoing chemotherapy: a review of the potential role for gonadotropin-releasing hormone agonists. Am J Obstet Gynecol. 2016;215(4):415–22.
27. Demeestere I, Brice P, Peccatori FA, Kentos A, Dupuis J, Zachee P, et al. No Evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: final long-term report of a prospective randomized trial. J Clin Oncol. 2016;34(22):2568-74.
28. GEICAM. Proyecto El Álamo III, encuesta de evolución de pacientes con cancer de mama en hospitales del grupo GEICAM 1998–2001. Madrid 2014, ISBN:84-938762-5-9. http://www.geicam.org/images/stories/recursos/proyectoscientificos/estudios_observacionales/El_Alamo_III.pdf.
29. Practice Committee ISFP, Kim SS, Donnez J, Barri P, Pellicer A, Patrizio P, Rosenwaks Z, et al. Recommendations for fertility preservation in patients with lymphoma, leukemia, and breast cancer. J Assist Reprod Genet. 2012;29(6):465–8.
30. Lambertini M, Ceppi M, Poggio F, Peccatori FA, Azim HA Jr, Ugolini D, et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol. 2015;26:2408–19.
31. Feichtinger M, Rodriguez-Wallberg KA. Fertility preservation in women with cervical, endometrial or ovarian cancers. Gynecol Oncol Res Pract. 2016;27(3):8.
32. Fastrez M, Houba C, Vandromme J, Rozenberg S. Fertility-sparing management of gynecological cancers. Maturitas. 2015;82(2):141–5.
33. Jadoul P, Dolmans MM, Donnez J. Fertility preservation in girls during childhood: is it feasible, efficient and safe and to whom should it be proposed? Hum Reprod Update. 2010;16:617–30.
34. Hussein AA, Tran ND, Smith JF. Fertility preservation for boys and adolescents facing sterilizing medical therapy. Transl Androl Urol. 2014;3(4):382–90.
35. Gawade PL, Oeffinger KC, Sklar CA, Green DM, Krull KR, Chemaitilly W, et al. Lifestyle, distress, and pregnancy outcomes in the Childhood Cancer Survivor Study cohort. Am J Obstet Gynecol. 2015;212(1):47.
36. Tarín JJ, García-Pérez MA, Cano A. Obstetric and offspring risks of women’s morbid conditions linked to prior anticancer treatments. Reprod Biol Endocrinol. 2016;14(1):37.
37. Azim HA, de Azambuja E, Colozza M, Bines J, Piccart MJ. Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann Oncol. 2011;22(9):1939-47. doi:10.1093/annonc/mdq683.